Business Wire

CA-OPENGATE-CAPITAL

3.5.2021 08:02:12 CEST | Business Wire | Press release

Share
OpenGate Capital Completes Sale of Bois & Matériaux to Chausson Matériaux S.A.S

OpenGate Capital , a global private equity firm, announced today the close of its sale of Bois & Matériaux (“B&M”) to Chausson Matériaux, a major building materials distribution company. The agreement was initially signed in January 2021 and terms were not disclosed.

With headquarters in Pacé, France, and more than 130 branches in the country, B&M is one of the leading building materials distributors in France. During the five-year period the business was owned by OpenGate, the business was fully revitalized under the leadership of CEO Yves Martin, and with the support of OpenGate’s operations team.

Julien Lagrèze, Partner and Head of Europe at OpenGate Capital, commented, “When we first looked at B&M, we saw a business that was underperforming and had vast opportunity. Our deep knowledge of investing in France and understanding of the building materials market motivated us to acquire the operationally complex business. OpenGate’s strategy focused on bottom line improvement, building a stronger, more resilient business with improved operations, and seamlessly integrating with management in a short time since consummating the acquisition. I want to thank CEO Yves Martin and the OpenGate team for their tremendous accomplishments.”

Throughout OpenGate’s ownership, the business experienced significant EBITDA growth. At acquisition, the business had approximately €5.8 million of EBITDA. Following the sale of a non-core business line, Guimier, in 2017, EBITDA was approximately €2.4 million. From the period 2017 through the end of 2020, B&M’s EBITDA expanded to €28.6 million, representing an increase of 10x in three years. This transformational growth was achieved through the execution of OpenGate’s investment thesis and operational process during a cycle of turbulent market conditions including the global pandemic. Operational achievements include:

  • Completing a carve-out and transition from UK-based parent company
  • Closing non-profitable branches
  • Improving purchasing through a rationalization of the product range and supplier base
  • Implementing a sales efficiency program to improve the sales organization, processes and tools
  • Streamlining the back office functions and organization
  • Creating a new, fully optimized logistic platforms
  • Developing an innovative digital pricing tool in order to preserve and optimize margin

B&M CEO Yves Martin stated, “The partnership was completely different from other private equity firms. From the outset, OpenGate understood B&M, and the fast start was attributed to their operations and M&A teams collaborating. OpenGate’s presence in both the United States and Europe, with the French team very rooted into the nuances of the local market, gave us confidence at the onset of our relationship. OpenGate was resilient and patient, allowing B&M time to implement change in the best manner, which is not the normal private equity approach.”

“With the exit, B&M is at one of the most interesting periods in the French building materials sector in years. It was built as the second national business in the country with no room for a number three player. The sale to Chausson paves a new, bright future with access to the best projects in France or pan-European in the next 10 years,” said Martin.

B&M has more than 2,100 employees and operations across the northern region of France with two main networks: Réseau Pro and Panofrance.

About OpenGate Capital

OpenGate Capital is a global private equity firm specializing in the acquisition and operation of businesses to create new value through operational improvements, innovation, and growth. Established in 2005, OpenGate Capital is headquartered in Los Angeles, California, with a European office in Paris, France. OpenGate’s professionals possess the critical skills needed to acquire, transition, operate, build, and scale successful businesses. To date, OpenGate Capital, through its legacy and fund investments, has executed more than 30 acquisitions including corporate carve-outs, management buyouts, special situations, and transactions with private sellers across North America and Europe. To learn more about OpenGate, please visit www.opengatecapital.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye